A share price of Xencor Inc [XNCR] is currently trading at $25.87, up 5.72%. An important factor to consider is whether the stock is rising or falling in short-term value. The XNCR shares have gain 7.12% over the last week, with a monthly amount glided 30.46%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update. In a post published today on Yahoo Finance, Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024.
From an analyst’s perspective:
Xencor Inc [NASDAQ: XNCR] stock has seen the most recent analyst activity on May 19, 2023, when BofA Securities initiated its Buy rating and assigned the stock a price target of $42. On October 13, 2022, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $58 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $37 on September 21, 2022. BMO Capital Markets started tracking with a Outperform rating for this stock on February 11, 2022, and assigned it a price target of $54. In a note dated January 21, 2022, SMBC Nikko initiated an Outperform rating and provided a target price of $60 on this stock.
Xencor Inc experienced fluctuations in its stock price throughout the past year between $16.49 and $34.20. Currently, Wall Street analysts expect the stock to reach $56 within the next 12 months. Xencor Inc [NASDAQ: XNCR] shares were valued at $25.87 at the most recent close of the market. An investor can expect a potential return of 116.47% based on the average XNCR price forecast.
Analyzing the XNCR fundamentals
Trailing Twelve Months sales for Xencor Inc [NASDAQ:XNCR] were 145.26M which represents 116.73% growth. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.78 points at the first support level, and at 23.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.58, and for the 2nd resistance point, it is at 27.29.
Xencor Inc [XNCR] reported earnings per share of -$0.4 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.73/share, meaning a difference of $0.33 and a surprise factor of 45.20%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.37 per share as compared to estimates of -$0.8 per share, a difference of $0.43 representing a surprise of 53.80%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xencor Inc [NASDAQ:XNCR] is 10.77. On the other hand, the Quick Ratio is 10.77, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 10.84, the price to book ratio is 2.35.
Transactions by insiders
Recent insider trading involved GORMAN KEVIN CHARLES, Director, that happened on Feb 13 when 53.0 shares were purchased. SR. VICE PRESIDENT & CSO, Desjarlais John R completed a deal on Feb 13 to sell 54108.0 shares. Meanwhile, PRESIDENT & CEO Dahiyat Bassil I sold 45000.0 shares on Dec 29.
